期刊文献+

肝癌患者血浆肿瘤坏死因子及其可溶性受体I的意义 被引量:3

The significance of plasma TNF and its soluble receptor I for patients with primary hepatocellular carcinoma
下载PDF
导出
摘要 目的:探讨肝癌患者血浆TNF和sTNFR-I的临床意义 。方法:分别用放射免疫法和ELISA法检测36例肝癌患者血浆TNF和sTNFR-I 。结果:肝癌患者血浆TNF、sTNFR-I均显著高于肝硬变和正常人,sTNFR-I水平与AFP、TB、g-GT、ALP无关,与血清白蛋白水平呈负相关,III、IV期或门脉癌栓患者sTNFR-I高于 II期或门脉无癌栓患者,TNF与分期及门脉癌栓无关;有效治疗后sTNFR-I水平明显降低。结论:sTNFR-I可能参与了肿瘤细胞的免疫逃避机制,检测sTNFR-I有助于了解肝癌患者的免疫状态、病程分期、判断预后、监测治疗,临床价值优于TNF测定。 Objective: To investigate the clinical significance of measurement of sTNFR-I and TNF in patients with primary hepatocellular carcinoma (PHC). Methods: Plasma TNF and sTNFR-I levels were measured in 36 patients with PHC by radioimmunoassay and ELISA respectively. Results: Both plasma levels of TNF and sTNFR-I in PHC were significantly higher than those in liver cirrhosis and healthy controls, which did not correlate with AFP, total bilirubin, g-GT, ALP, but negatively correlated with serum albumin concentration. sTNFR-I in patients with PHC of stage TNM III-IV or with portal embolus were significantly higher than those of stage II or without portal embolus. TNF correlated with neither stage nor portal embolus. sTNFR-I decreased significantly after effective therapy. Conclusion: sTNFR-I possibly involved in the immunological escape mechanism of tumor cells. Plasma sTNFR-I levels in patients with PHC correlated with disease status closely and the determination could be helpful to recognize patients' immune status and staging of disease , predict prognosis, monitor therapy with a clinical value much better than TNF.
作者 刘超 姚榛祥
出处 《重庆医科大学学报》 CAS CSCD 2001年第1期48-50,共3页 Journal of Chongqing Medical University
关键词 肝肿瘤 肿瘤坏死因子 肿瘤坏死因子受体 可溶性受体 TNF sTNFR-1 Liver neoplasm;Tumor necrosis factor;Tumor necrosis factor receptor
  • 相关文献

参考文献6

  • 1[1]Diez-Kuiz A,Tilz GP, Zangerle R, et al. Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis[J]. Eur J Haematol, 1995; 54(1): 1-6.
  • 2[2]Elsasser-Beile U, Gallati H, Weber W, et al. Increased plasma concentrations for type Ⅰ and Ⅱ tumor necrosis factor receptors and IL-12 receptors in cancer patients [J]. Tumor Biol,1994; 15(1): 17-23.
  • 3[3]Langkopf F, Atzpodien J. Soluble tumor necrosis factor receptors as prognostic factors in cancer patients [J]. Lancet,1994; 344: 57-60.
  • 4[4]Selinsky CL, Boroughs KL, Halsey WA, et al. Multifaceted inhibition of anti-tumor immune mechanism by soluble tumor necrosis factor receptor type I[J]. Immunology, 1998; 94(1): 88-93.
  • 5[5]Ott MG, Mannel DN, Gallati H, et al. Peripheral natural killer cell activity and intraperitoneal soluble p55 TNFR in patients with malignant ascites: two possible indicators for response to intraperitoneal combined TNT-α and IFN-γ [J].Cancer lmmunol Immunother, 1996; 42:31-37.
  • 6[6]Jablonska E, Pietruska. Soluble TNF receptors release by polymorphonuclear cells and the serum levels in breast cancer patients before and after treatment[J]. Neoplasma. 1998;45(1): 17-20

同被引文献19

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部